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Dear	  Prof.	  Kam	  W.	  Leong,	  
	  
Herewith	   I	   submit	   the	   revised	  version	  of	   the	  manuscript	   (Ref.	  No.	   jbmt31220)	  entitled	  
“Complete	  Regression	  of	  Breast	  Tumour	  with	  a	  Single	  Dose	  of	  Docetaxel-­‐entrapped	  Core-­‐Cross-­‐
linked	  Polymeric	  Micelles”.	  
	  
We	  appreciate	  the	  positive	  comments	  from	  the	  reviewers.	  The	  reviewer#3	  has	  raised	  a	  
very	  minor	  comment	  on	  the	  drug	  release	  property	  of	  our	  polymeric	  micelles.	  The	  reviewer	  found	  
it	  interesting	  that	  in	  our	  study	  75%	  of	  docetaxel	  was	  released	  within	  4	  days,	  whereas	  only	  <20%	  
physically	   loaded	  paclitaxel	  was	   released	   from	  another	  CCL-­‐PM	  system	   (Yang	  et	   al,	   2011).	  We	  
checked	   the	   details	   of	   the	   study	   published	   by	   Yang	   and	   co-­‐workers	   and	   found	   two	   major	  
differences	   in	   these	   studies.	   The	   first	   difference	   is	   in	   the	   block	   polymer	   compositions	   as	   they	  
used	  PEG-­‐PAC-­‐PCL/Gal-­‐PEG-­‐PCL	  and	  we	  have	  used	  mPEG-­‐b-­‐pHPMAmLacn	  polymer.	  The	  second	  
difference	  is	  that	  we	  have	  chemically	  conjugated	  docetaxel	  to	  the	  polymer	  while	  they	  have	  only	  
entrapped	  paclitaxel	  physically	  or	  non-­‐conjugated.	  In	  our	  view,	  these	  systems	  are	  quite	  different	  
in	   terms	   of	   their	   polymer	   composition,	   entrapment	   method	   and	   also	   the	   drugs,	   which	  make	  
them	  difficult	  to	  compare	  for	  their	  drug	  release	  properties.	  
	  
In	   the	   revised	  version,	  we	  have	   imporved	   the	  quality	  of	   figures	  and	  checked	   for	  other	  
requirments.	  We	  hope	  that	  the	  revised	  version	  is	  acceptable	  for	  publication	  in	  this	  journal.	  
	  
Sincerely,	  
	  
Jai	  Prakash,	  Ph.D.	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Abstract 
Treatment with chemotherapy such as docetaxel (DTX) is associated with significant toxicity 
and tumour recurrence. In this study, we developed DTX-entrapped core-cross-linked 
polymeric micelles (DTX-CCL-PMs, 66 nm size) by covalently conjugating DTX to CCL-
PMs via a hydrolysable ester bond. The covalent conjugation allowed for sustained release of 
DTX under physiological conditions in vitro. In vivo, DTX-CCL-PMs demonstrated superior 
therapeutic efficacy in mice bearing MDA-MB-231 tumour xenografts as compared to the 
marketed formulation of DTX (Taxotere®). Strikingly, a single intravenous injection of DTX-
CCL-PMs enabled complete regression of both small (150 mm3) and established (550 mm3) 
tumours, leading to 100% survival of the animals. These remarkable antitumour effects of 
DTX-CCL-PMs are attributed to its enhanced tumour accumulation and anti-stromal activity. 
Furthermore, DTX-CCL-PMs exhibited superior tolerability in healthy rats as compared to 
Taxotere. These preclinical data strongly support clinical translation of this novel 
nanomedicinal product for the treatment of cancer. 
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Polymeric micelles, Docetaxel, Breast cancer, Tumour targeting, Antitumour efficacy 
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1. Introduction  
Despite many marketed anticancer agents, treatment of solid tumours still represents a major 
medical challenge. Conventional chemotherapeutics suffer from a narrow therapeutic index as 
a result of poor pharmacokinetic and tissue distribution profiles. Besides that, biological 
barriers at the tumour site such as abnormal blood supply, abundant tumour stroma and high 
intratumoural pressure limit intratumoural drug penetration, leading to suboptimal therapeutic 
drug levels [1, 2]. To improve the therapeutic index of chemotherapeutics, nanoparticulate 
systems offer a set of tools to achieve enhanced intratumoural drug accumulation, sustained 
intratumoural drug release and reduced side effects [3-5].  
Compared to normal tissues, tumour tissues generally have hyperpermeable vasculature and 
poor lymphatic drainage, which allow extravasation and greater retention of nanoscale 
medicines in tumours, the phenomenon known as the Enhanced Permeability and Retention 
(EPR) effect [6]. By exploiting the EPR effect, nanoparticles can preferentially localize in 
tumours and enhance local drug concentration [7-9]. A few passively targeted anticancer 
nanomedicines such as Doxil® (liposomal doxorubicin) and DaunoXome® (liposomal 
daunorubicin) are already in the market [10] and others, such as polymeric micelles (e.g. 
NK105 for paclitaxel delivery) and polymer conjugates (e.g. Opaxio™ for paclitaxel delivery), 
are in advanced clinical trials [11-13]. Although the currently marketed nanomedicines have 
shown benefits in subsiding the side effects, a gain at the level of antitumour activity has only 
marginally been achieved [12, 14-16]. Also in preclinical studies with nanomedicines, 
complete regression of solid tumours has hardly been reported. The latter shortcoming is 
likely attributed to a poor EPR effect and /or insufficient drug release from the extravasated 
nanoparticles, leading to sub-therapeutic drug levels. Moreover, the delivery of anticancer 
agents can also be significantly limited by the physical barrier of stroma in tumour tissues 
[17]. Tumour stroma (including cancer-associated fibroblasts, immune cells and extracellular 
*Manuscript
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matrix) is the supporting tissue adjacent to tumour cells, which plays a pivotal role in tumour 
growth and progression [18]. Elimination of activated stroma has been considered as a 
potential approach to anti-cancer therapy [17, 18]. Altogether, the development of a 
nanomedicine with efficient tumour accumulation, sufficient intratumoural drug release and 
anti-stromal activities is very likely mandatory for achieving optimal antitumour activity.  
Docetaxel (DTX), a potent anti-mitotic chemotherapeutic agent, acts by binding to 
microtubules and thereby interfering with cell division. DTX is approved for the treatment of 
locally advanced or metastatic breast cancer, gastric cancer, hormone-refractory prostate 
cancer and non-small cell lung cancer [19-21]. In spite of its wide clinical use, serious side 
effects are often observed in patients such as acute hypersensitivity reactions, cumulative 
fluid retention, neurotoxicity, febrile neutropenia, myalgia, nasolacrimal duct stenosis and 
asthenia [22, 23]. Several nanosized vehicles have been developed in recent years to improve 
the therapeutic index of DTX, including polymeric nanoparticles (NPs) [24], drug-polymer 
conjugates [25], polymeric micelles [26], lipid-based nanocarriers [27] and inorganic NPs 
[28]. Many of these nanoparticulate systems demonstrated superior antitumour activity 
compared to the marketed formulation in preclinical models, yet complete tumour regression 
was rarely reported and most of them were not (fully) evaluated for their tolerability profiles.  
Core-crosslinked polymeric micelles (CCL-PMs) have shown prolonged circulation kinetics 
upon intravenous (i.v.) administration and enhanced tumour accumulation in various tumour 
models [29-31]. In the present study, we developed CCL-PMs composed of poly(ethylene 
glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate] (mPEG-b-p(HPMAm-Lacn) 
copolymers to deliver DTX to tumours after i.v. administration. To assure sufficient drug 
release from the extravasated CCL-PMs, we conjugated DTX covalently to CCL-PMs via a 
hydrolysable ester linker to allow controlled drug release [32]. In the present study, the 
antitumour effect of DTX-CCL-PMs and Taxotere was compared after multi-dose or a single-
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dose i.v. administration at various doses to tumour-bearing mice. Furthermore, to obtain the 
safety profile of DTX-CCL-PMs for future clinical translation, the pharmacokinetics (PK) and 
tolerability profile of DTX-CCL-PMs were examined in healthy rats. 
 
2. Materials and methods 
2.1. Materials 
Docetaxel (DTX) was obtained from Phyton Biotech GmbH (Ahrensburg, Germany). N,N'-
dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine (DMAP), 4-methoxyphenol, 
methacrylic anhydride, ammonium acetate, formic acid, Mukaiyama‟s reagent (2-chloro-1-
methylpyridinium iodide), oxone, potassium persulfate (KPS), lactic acid, 
tetramethylethylenediamine (TEMED) and trifluoroacetic acid (TFA) were obtained from 
Sigma Aldrich (Zwijndrecht, The Netherlands). Dichloromethane (DCM), N,N-
dimethylformamide (DMF) and acetonitrile (ACN) were purchased from Biosolve 
(Valkenswaard, The Netherlands). Absolute ethanol and triethylamine were purchased from 
Merck (Darmstadt, Germany). The initiator (mPEG5000)2-ABCPA was synthesized as 
described previously [33]. 2-(2-(Methacryloyloxy)ethylthio)acetic acid (linker) was 
synthesized as described previously [32]. Taxotere® was purchased from Sanofi-Aventis 
(Berlin, Germany). The other chemicals were used as received.  
2.2. Preparation of docetaxel-entrapped core-cross-linked polymeric micelles  
First, DTX-derivative (DTXL) was synthesized in a two-step procedure, as shown in Fig. 1A. 
The detailed synthesis, purification and analysis of DTXL are described in supplementary 
methods. A block copolymer containing monomethoxy poly(ethylene glycol) (mPEG, 
Mn=5000) as hydrophilic block and a random copolymer of N-2-hydroxypropyl 
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methacrylamide monolactate (HPMAmLac1) and N-2-hydroxypropyl methacrylamide 
dilactate (HPMAmLac2) as thermosensitive block was synthesized as described previously 
[29, 34]. Docetaxel-entrapped core-cross-linked polymeric micelles (DTX-CCL-PMs) were 
prepared essentially using the fast heating method [35]. In brief, an ice-cold aqueous solution 
of methacrylated mPEG-b-pHPMAmLacn block copolymer (830 μL, 24 mg/mL) was mixed 
with TEMED (25 μL, 120 mg/mL) dissolved in ammonium acetate buffer (150 mM, pH 5). 
Subsequently, DTXL (100 μL, 20 mg/mL DTX equivalents, dissolved in ethanol) was added, 
followed by rapid heating to 60 °C while stirring vigorously for 1 minute to form polymeric 
micelles. The micellar dispersion was then transferred into a vial containing KPS (45 μL, 30 
mg/mL) dissolved in ammonium acetate buffer (150 mM, pH 5). The polymeric micelles 
were covalently stabilized by crosslinking the methacrylate moieties in DTXL and block 
polymer in a N2 atmosphere for 1 hour at RT, to obtain DTX-CCL-PMs. The final feed 
concentrations of block copolymer and DTXL (DTX equivalents) were 20 and 2 mg/mL, 
respectively. Next, the DTX-CCL-PMs dispersion was filtered through a 0.2 μm cellulose 
membrane filter to remove potential aggregates. DTX-CCL-PMs dispersions were purified 
and concentrated for 10 times using a KrosFlo Research IIi Tangential Flow Filtration (TFF) 
System equipped with modified polyethersulfone (mPES) MicroKros® filter modules 
(MWCO 500 kDa). Ammonium acetate buffer (20 mM, pH 5) containing 130 mM NaCl was 
used as the washing buffer for TFF and referred to as “vehicle” in the following sections.  
2.3. Characterization of DTX-CCL-PMs by DLS, TEM and UPLC  
The size of DTX-CCL-PMs was measured by dynamic light scattering (DLS) using a 
Malvern ALV/CGS-3 Goniometer. DLS results are given as a z-average particle size diameter 
(Zave) and a polydispersity index (PDI).  
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Transmission electron microscopy (TEM) analysis of DTX-CCL-PMs was conducted using a 
Philips Tecnai 12 microscope equipped with a Biotwin lens and a LaB6 filament, operated at 
120 kV acceleration voltage. Glow discharged grids (copper 200 mesh grid with a carbon-
coated thin polymer film, Formvar on top) were used for sample preparation and 2% uranyl 
acetate (w/v) was used as a negative stain. Images were captured with a SIS Megaview II 
CCD camera and processed with AnalySIS software. 
The contents of free DTX, free DTXL, total DTX and polymer in DTX-CCL-PMs dispersions 
were determined by ultra-performance liquid chromatography (UPLC) as described in 
supplementary methods. The drug entrapment efficiency (EE) and drug loading (DL) were 
calculated using the UPLC data as follows: 
       Amount of drug entrapped ×100% 
EE = 
           Amount of drug added 
 
              Amount of drug entrapped × 100% 
DL = 
      Amount of polymer + Amount of drug entrapped 
 
The amount of drug entrapped was calculated as: amount of drug entrapped = amount of total 
DTX content – amount of free DTX – amount of free DTXL (DTX equivalents).  
2.4. In vitro docetaxel release from docetaxel-entrapped core-crosslinked polymeric micelles 
The in vitro release of DTX from DTX-CCL-PMs was measured in phosphate buffer (100 
mM, pH 7.4) containing 15 mM NaCl, whole rat blood and whole human blood at 37°C, 
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respectively. DTX-CCL-PMs were incubated at 37°C in different matrices and the samples 
were collected at different time points and analysed for released DTX content using UPLC. In 
brief, DTX-CCL-PMs were diluted in phosphate buffer (100 mM, pH 7.4) containing 15 mM 
NaCl and 1% polysorbate 80 (v/v). The concentration of released DTX was determined by 
injecting 7 μL of the mixture into a UPLC system (Waters, USA) equipped with an 
ultraviolet/visible light detector (TUV, Waters). An Acquity HSS T3 1.8 μm column (50 × 2.1 
mm) (Waters) was used with a gradient from 100% eluent A (70% H2O/30% ACN/0.1% 
formic acid) to 100% B (10% H2O/90% ACN/0.1% formic acid) in 11 minutes with a flow of 
0.7 mL/min and UV-detection at 227 nm. DTX standards dissolved in ACN were used to 
prepare a calibration curve (linear between 0.5 and 110 μg/mL). In the case of whole blood, 
rat or human whole blood was first incubated at 37
o
C for 10 minutes. Next, blood (85 μL) was 
spiked with DTX-CCL-PMs (15 μL) and incubated at 37oC for various lengths of time. After 
incubation, water (100 μL) was added to the mixture, followed by ACN (600 μL). The 
reaction mixture was vortexed for 30 seconds and centrifuged at 10,000 x g for 5 minutes at 
20
o
C. Thereafter, the supernatant (500 μL) was added to water (100 μL) and 7 μL of the 
resulting mixture was injected into the UPLC system. An Acquity HSS T3 1.8 μm column (50 
× 2.1 mm) (Waters) was used with an isocratic run of 3.5 minutes (mobile phase: 55% 
H2O/45% ACN/0.1% formic acid) with a flow of 0.7 mL/min and UV-detection at 227 nm. 
Only DTX and 7-epi-DTX (the major degradation product of DTX [36, 37]) were taken into 
account for the calculation of the percentage release of DTX, so not the other degradation 
products of DTX [38]: 
% Release of DTX =    
Amount of DTX + Amount of 7-epi-DTX   ×100% 
               Amount of total DTX 
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2.5. Efficacy studies in MDA-MB-231 xenografts  
All animal experiments were approved by the local ethical committee. All animals were 
housed in a temperature-controlled room (21±3°C), with 55±15% relative humidity, and a 
photoperiod of 12/12 h. Female NCr nu/nu mice (8-12 week old, Charles River) were used to 
induce MDA-MB-231 breast tumour model. Tap-water and pelleted rodent food (SM R/M-Z 
from SSNIFF® Spezialdiäten GmbH, Germany) were provided to the animals. To induce 
tumours, 5×10
6
 MDA-MB-231 human breast tumour cells were subcutaneously implanted in 
the mammary fat pad of the mice. When tumours attained ~150 mm
3
 size (small, early stage) 
or ~550 mm
3
 size (established, late-stage), mice received either a single i.v. injection or 
multiple injections (weekly i.v. bolus injections for 3 weeks) of either Taxotere, DTX-CCL-
PMs or vehicle in the tail vein. The details of the doses, injections and duration of the 
experiment are specified in the figure (captions). Tumour volume was analysed by caliper 
measurement biweekly. Animals were monitored individually. The measurement was 
terminated when a tumour volume of 1500 mm
3
 was attained. In the case of animals exiting 
the study prematurely, the tumour volume data were carried forward until the endpoint (i.e. 
when ≤ 50% of the animals remained in the study), which was the point when data plotting 
stopped. % Survival was calculated using a cut-off tumour volume of 1500 mm
3
 as a 
surrogate for mortality. 
2.6. Effect of the DTX-CCL-PMs on the tumour stromal proteins  
In the MDA-MB-231 tumour model, when the mean tumour volume reached ~150 mm
3
, a 
single i.v. injection of Taxotere (30 mg DTX/kg), DTX-CCL-PMs (125 mg DTX/kg) or 
vehicle was administered. Tumours were isolated from mice 4 days after the injections. The 
collected tumours were frozen at -80
o
C till analysis for biomarkers for tumour stroma using 
Western Blot analyses, as described in the supplementary methods. 
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2.7. Tumour accumulation of DTX-CCL-PMs in MDA-MB-231 xenografts 
In the MDA-MB-231 tumour model, when the mean tumour volume reached ~150 mm
3
, mice 
received a single dose i.v. bolus injection of Taxotere (30 mg/kg) or DTX-CCL-PMs (30 
mg/kg). Tumours were collected on day 2 or day 4 post-administration and homogenized to 
determine total and released DTX contents using HPLC-MS/MS (see supplementary 
methods). 
2.8. Pharmacokinetics and tolerability studies in rats 
Charles River Crl:CD (SD) rats were used for the in vivo studies. For pharmacokinetic studies, 
rats were randomly divided into groups of six (three female and three male). A single i.v. 
bolus injection of DTX-CCL-PMs was given into the tail vein of rats at escalating doses of 
1.5, 7.5 or 24 mg/kg. Blood samples (~200 µL) were collected at different time points in 
EDTA vials and meanwhile systemic tolerance was observed. The content of total DTX in rat 
whole blood was determined using HPLC-MS/MS (see supplementary methods). 
Pharmacokinetic evaluation of blood data was performed using WinNonlin, version 6.3 
(Pharsight Corporation, Mountain View, CA, USA). 
For tolerability studies, acute toxicity and 5-day repeated dose toxicity studies were 
performed in healthy rats. For the acute toxicity study, a single i.v. bolus injection of DTX-
CCL-PMs was administered at a dose of 7.5 mg/kg or 24 mg/kg and clinical observations 
were recorded systemically for 2 weeks. In addition, the change of body weight and food 
consumption were also monitored. For 5-day repeated dose toxicity study, an i.v. injection of 
DTX-CCL-PMs (9.7 mg/kg/day) or Taxotere (6.7 mg/kg/day) was administered into the tail 
vein of rats daily for five consecutive days. Animals were observed for any signs of 
behavioural changes, reaction to treatment and illness before and after each dosing. On test 
day 6, the animals were sacrificed, dissected and inspected microscopically. The size and 
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weight of these organs, as well as any abnormalities in the appearance of these organs were 
recorded. In addition, clinical haematological parameters and serum biochemistry parameters 
in these animals were analysed. 
 
3. Results 
3.1. Synthesis and purification of DTX-CCL-PMs 
DTX-CCM-PMs were prepared in three main steps: (i) derivatization of DTX; (ii) synthesis 
of methacrylated block copolymer and (iii) preparation of DTX-CCL-PMs. The 
methacrylated DTX derivative (DTXL) was synthesized in a two-step reaction (Fig. 1A). First, 
DTX was esterified at its C-2‟ hydroxyl group with a methacrylated linker containing a 
sulfide ester. Next, the sulfide bond was oxidized to a sulfone to obtain DTXL. The 
synthesized DTXL was purified by column chromatography and obtained as a white solid 
with high purity (> 95%). The identity and purity of the compound were confirmed by 
1
H 
NMR, LCMS-UV and UPLC-UV (Fig. S1). Methacrylated block copolymer composed of a 
hydrophilic mPEG block and a random block of pHPMAm-Lac1/Lac2 was prepared via 
radical polymerization (75% yield) and its characteristics were in good agreement with 
previous data [30] (Table S1). DTXL was covalently linked to CCL-PMs upon 
polymerization of the methacrylate moieties in DTXL as well as in the polymer lactate side 
chain to obtain DTX-CCL-PMs as an opalescent dispersion. By means of tangential flow 
filtration (TFF), DTX-CCL-PMs were purified and concentrated to 20 mg DTX equiv. per 
mL. The mean particle size and polydispersity index (PDI) of DTX-CCL-PMs as determined 
by dynamic light scattering were 66 nm and < 0.1, respectively (Table S2), which are typical 
for CCL-PMs prepared from this type of block copolymer [32]. A transmission electron 
microscope (TEM) image showed spherical morphology and confirmed the homogenous size 
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distribution of DTX-CCL-PMs (Fig. 1C). DTX entrapment efficiency and loading were ca. 
75% (w/w) and ca. 12% (w/w) respectively.  
3.2. In vitro DTX release from DTX-CCL-PMs 
Hydrolysis of the ester bond linking DTX to the CCL-PMs allows native DTX to be released 
under physiological conditions (pH 7.4, 37
o
C) following first-order kinetics (Fig. 1D). Due to 
the degradation of DTX itself [36], the in vitro drug release did not reach 100% (Fig. S2). In 
addition to PBS (pH 7.4), the drug release profile of DTX-CCL-PMs was also evaluated in 
fresh rat and human blood, in which similar drug release kinetics was observed (Fig. 1D). 
Accordingly, DTX release kinetics is likely solely dependent on chemical hydrolysis of the 
ester linkage and is not influenced by e.g. enzymes present in biological fluids, enabling a 
predictable drug release profile in vivo. 
3.3. Dose-dependent effect of DTX-CCL-PMs on breast tumour growth 
To establish the therapeutic efficacy, the MDA-MB-231 human tumour xenograft model was 
used as an established in vivo model for breast cancer [39].  
Multiple dose study: The therapeutic efficacies of Taxotere and DTX-CCL-PMs were first 
assessed in MDA-MB-231 xenografts following three weekly i.v. injections in nude mice at a 
dose of 30 mg DTX/kg (referred as 30 mg/kg later), i.e. the maximum tolerated dose (MTD) 
of Taxotere in nude mice upon weekly i.v. administrations [40]. As shown in Fig. S3A, both 
Taxotere and DTX-CCL-PMs inhibited tumour growth effectively. However, Taxotere 
induced a significant (P<0.05) loss in body weight as compared to vehicle group while 
treatment with DTX-CCL-PMs did not induce any body weight loss (Fig. S3B). 
Single dose studies: Since the multiple dose study with DTX-CCL-PMs demonstrated high 
therapeutic efficacy and good tolerability in terms of body weight loss, studies with different 
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but single doses were carried out to find the best therapeutic outcome. When a tumour size of 
150-200 mm
3
 was attained, mice were treated with a single i.v. injection of equivalent dose of 
DTX (30 or 60 mg/kg) in Taxotere or DTX-CCL-PMs. As shown in Fig. 2A, at the dose of 30 
mg/kg, both Taxotere and DTX-CCL-PMs exhibited comparable antitumour activity till day 
51 post-administration. After that, animals from the Taxotere-treated group had to be 
sacrificed due to the attainment of humane end point (i.e. larger tumour volumes than allowed) 
in ≥ 50% animals. On the other hand, at a dose of 60 mg/kg, DTX-CCL-PMs significantly 
inhibited the tumour growth as opposed to Taxotere which did not show additional benefit 
compared to the 30 mg/kg dose, reaching the endpoint at day 54 (Fig. 2A). Remarkably, by 
virtue of the substantial tumour regression, 100% survival was achieved with a single dose of 
DTX-CCL-PMs (60 mg/kg) over the 79-day period of study (Fig. 2B). Regarding tolerability, 
a single i.v. injection of DTX-CCL-PMs did not result in body weight loss at both doses. In 
contrast, significant body weight loss was observed at day 5 and 9 with Taxotere treatments 
(P<0.05), indicating acute toxicity of Taxotere at these doses (Fig. S4). Yet, there was no 
benefit with Taxotere in inhibition of tumour growth after an increase of the dose from 30 to 
60 mg/kg. 
3.4. A single dose of DTX-CCL-PMs supresses tumours completely 
Although a single dose of DTX-CCL-PMs at 60 mg/kg markedly inhibited tumour growth, 
mice were not completely cured. As this dose was well tolerated, we examined the antitumour 
activity of DTX-CCL-PMs at a higher dose of 125 mg/kg. For Taxotere, a dose of 125 mg/kg 
was not approved by the local experimental animal committee given its known single dose 
MTD (i.e. 98 mg/kg) [41]. Considering the lack of benefit in antitumour effects and yet acute 
toxicity with Taxotere after doubling the dose to 60 mg/kg, a single dose of 30 mg/kg was 
selected for assessing comparative efficacy. Interestingly, we found that a single dose of 
DTX-CCL-PMs at 125 mg/kg completely abolished tumour growth in mice bearing tumours 
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of 150-200 mm
3
 size with a 100% tumour-free survival after the 62-day period of study (Fig. 
3A and 3B).  
One essential point in preclinical evaluation is that tumours are generally treated at early stage 
(i.e. small tumours that may not represent the clinical situation), which may overestimate the 
potency of a new anti-cancer therapy. Taking this aspect into account, we also assessed DTX-
CCL-PMs in mice bearing established tumours of approximately 550 mm
3
 size. As shown in 
Fig. 3C and Fig. 3D, Taxotere exhibited only a moderate antitumour effect in both early and 
advanced tumour models. Remarkably, a single dose of DTX-CCL-PMs (125 mg/kg) induced 
complete regression of established tumours leading to 100% tumour-free survival of these 
mice for 62 days (Fig. 3C and 3D). Moreover, no significant loss in body weight was 
observed in both treatment groups (Fig. S5). 
3.5. Intratumoural effect of DTX-CCL-PMs 
To investigate the intratumoural mechanisms for the tumour growth inhibition, we set up an 
experiment to study the intratumoural effect of the DTX-CCL-PMs within short duration of 4 
days. A single dose of Taxotere (30 mg/kg) or DTX-CCL-PMs (125 mg/kg) was injected 
intravenously into mice bearing tumours of approximately 150-200 mm
3
 size. After 4 days, 
tumours were isolated and analysed for biomarkers for tumour stroma with Western Blot 
analyses. The data revealed that treatment with DTX-CCL-PMs significantly reduced tumour 
stroma markers, as shown by the reduction in the protein expression of NG2 (a pericyte 
marker), α-SMA (a pericyte and cancer-associated fibroblast marker) and collagen-1 (a major 
extracellular matrix protein) (Fig. 4). In addition, there was also a clear reduction in β-tubulin 
expression (a marker for microtubules) after the treatment with DTX-CCL-PMs. In contrast, 
treatment with Taxotere showed no significant effects on any of these markers. These data 
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suggest that the antitumour effects of DTX-CCL-PMs are not only caused by the direct 
inhibitory effects on tumour cells but also by anti-stromal effects.  
3.6. Tumour accumulation of DTX-CCL-PMs in mice 
To characterize the tumour distribution of DTX-CCL-PMs in mice, the intratumoural levels 
of released DTX and total DTX (released plus entrapped) in tumour-bearing mice were 
measured at 2 and 4 days after a single i.v. administration of DTX-CCL-PMs or Taxotere at 
equivalent dose of 30 mg/kg. As illustrated in Fig. 5A, a single i.v. administration of DTX-
CCL-PMs (30 mg/kg) provided a 20-fold (2 days, P<0.01) and 59-fold (4 days, P<0.001) 
higher total DTX level as compared to Taxotere (30 mg/kg). In addition to the significantly 
enhanced total DTX levels, 2-fold (2 days) and 4-fold (4 days, P<0.05) higher released DTX 
levels were found in mice treated with DTX-CCL-PMs. Having expressed as the percentage 
of injected dose (%ID) in tumour, DTX-CCL-PMs rendered 5-fold (P<0.05) higher released 
DTX levels and 77-fold (P<0.001) higher total DTX levels in tumour as compared to 
Taxotere 4 days after the onset of treatment. 
3.7. Pharmacokinetic studies in healthy rats 
In the present study, the superior efficacy of DTX-CCL-PMs as well as enhanced tumour 
accumulation was demonstrated in tumour-bearing mice. To continue the development of 
DTX-CCL-PMs towards clinical evaluation, the PK and tolerability profile were evaluated in 
healthy rats (as required by regulatory authorities). 
PK studies with a single i.v. administration of DTX-CCL-PMs were conducted in healthy rats 
at the escalating doses (Fig. 5B). The PK evaluation at various doses is given in Table 1. 
These studies demonstrated that DTX-CCL-PMs had an elimination half-life of 15.9 ± 0.7 h 
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and the extrapolated AUC from zero to infinity (AUC0-∞) at different doses linearly correlated 
with the administered dose of DTX-CCL-PMs (Fig. 5C, R
2
=0.997).  
3.8. Tolerability studies in healthy rats 
To investigate the potential toxicity of DTX-CCL-PMs, both acute and 5-day repeated dose 
toxicities were examined in healthy rats. With respect to acute toxicity, a single i.v. 
administration of DTX-CCL-PMs at 7.5 mg/kg or 24 mg/kg was well tolerated albeit a 
slightly reduced (transient) motility for both male and female animals at 24 mg/kg. To 
establish repeated dose toxicity, DTX-CCL-PMs or Taxotere was administered intravenously 
to male and female rats daily for 5 consecutive days. Taxotere was administered intravenously 
at a dose of 6.7 mg/kg/day (i.e. 40 mg/m
2
), the dose often used for toxicity evaluation e.g. by 
Burstein et al. [42] whereas a 45% higher dose of DTX-CCL-PMs (9.7 mg/kg/day) was 
administered to the animals considering the superior tolerability of the DTX-CCL-PM as 
demonstrated in the acute toxicity study. 
Although no mortality occurred, DTX-related target organ toxicities were observed in both 
groups as reflected by food consumption, diarrhea, size and weight of thymus as well as 
weight of spleen (Table S3). However, compared to Taxotere, these toxicities were 
substantially reduced in animals that received DTX-CCL-PMs despite a 45% higher dose 
given. In addition, hematology and serum biochemistry parameters were also examined 
(Table S4 and Table S5). Compared to DTX-CCL-PMs, the hematological changes such as 
panleukopenia, thrombocytopenia and reduction in reticulocytes were significantly higher in 
rats that received Taxotere.  
4. Discussion 
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Long-circulating nanoparticles such as polymeric micelles are exploited with the aim to 
improve solubility, stability, pharmacokinetics and tumour accumulation of drugs by means 
of their capacity to encapsulate and target drugs to tumours via the EPR effect [3, 43-45]. 
However, low stability of micelles in circulation and uncontrolled drug release rate remain 
critical issues [29, 44]. As demonstrated in the present study, covalent conjugation of 
docetaxel (DTX) to CCL-PMs not only provided small-sized (66 nm) and stable micellar 
nanoparticles but also enabled prolonged systemic circulation with enhanced tumour 
accumulation and sustained release of DTX. Convincingly, treatment with a single 
administration of DTX-CCL-PMs led to complete regression of the human xenograft MDA-
MB-231 breast tumours in mice. This remarkable antitumour efficacy was confirmed by the 
significantly enhanced tumour accumulation of targeted DTX, attributed to the prolonged 
systemic circulation of DTX-CCL-PMs and the EPR effect [29].  
The synthesis of DTXL is straightforward. Although there are four hydroxyl groups in DTX, 
the methacrylated linker was selectively conjugated to DTX at its C-2‟ hydroxyl group, the 
most amenable and sterically available group for structural modifications [46, 47]. Such 
selective conjugation was also demonstrated in the work of Liu et al. in which PEG was 
selectively conjugated to DTX at the 2‟-hydroxyl position [41]. Importantly, the 
manufacturing of DTX-CCL-PMs is a well-controlled step with confirmed scalability (up to 
multi-liters under Good Manufacturing Practices conditions), excellent batch-to-batch 
reproducibility and tailorable concentration (e.g. 5-20 mg DTX equiv. per mL) (data not 
shown). Drug release from polymeric micelles is generally dependent on the degradation of 
the polymers and/or diffusion of the drug from the micelles, which leads to uncontrolled 
release of the encapsulated drug [48]. However, as shown in this study, a hydrolysis-sensitive 
covalent linkage of DTX to the CCL-PMs resulted in sustained release of the drug under 
physiological conditions (Fig. 1D). As indicated in Fig. 1D, the release of DTX from DTX-
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CCL-PMs is solely dependent on ester hydrolysis. Such hydrolysis from the CCL-PMs was 
also reported by Crielaard and coworkers with dexamethasone [32]. Compared to 
dexamethasone with the same derivatized unit (t1/2= 8.9 ± 0.1 days), DTX was released from 
the CCL-PMs at a much faster rate (t1/2=1.5 ± 0.3 days). Ester hydrolysis kinetics is 
influenced by the electron-density of the surrounding moieties of the ester bond. Unlike 
dexamethasone, the derivatization of DTX occurred at a secondary hydroxyl group, which 
gave rise to a reduced electron density at 2‟ carbon and therefore faster hydrolysis kinetics 
under physiological conditions.  
With respect to the tumour accumulation, a single i.v. administration of DTX-CCL-PMs (30 
mg/kg) rendered not only significantly greater total DTX levels but also higher released DTX 
levels in tumours as compared to Taxotere administration at the equivalent dose (Fig. 5A). 
The enhanced released DTX levels in tumour could be ascribed to the slow release of DTX 
from the CCL-PMs within the tumour microenvironment and possibly the accumulation of 
native DTX released from the circulating DTX-CCL-PMs. High tumour accumulation of 
DTX-CCL-PMs and slow intratumoural release of DTX obviously attributed to the strong 
antitumour effect of DTX-CCL-PMs. 
At the reported MTD of DTX, i.e. 30 mg/kg (weekly injections) [40], DTX-CCL-PMs and 
Taxotere showed similar tumour inhibitory effects after three weekly i.v. injections. However, 
DTX-CCL-PMs had a clear benefit in terms of body weight in comparison to Taxotere (Fig. 
S3B). The absence of body weight loss in mice that received DTX-CCL-PMs was most likely 
attributed to the covalent entrapment of DTX within the CCL-PMs and thereby the lower 
„active‟ DTX concentration in systemic circulation and lower exposure of normal tissues as 
compared to Taxotere.  
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Based on the high efficacy and good tolerability of DTX-CCL-PMs after multiple dosing, 
single dose studies were carried out to determine the therapeutic superiority over the marketed 
formulation. Compared to Taxotere, a clear gain in therapeutic efficacy with an increased 
dose of DTX-CCL-PMs (from 30 to 60 mg/kg) underlined the benefit of the targeted DTX. 
The lack of the benefit with Taxotere can be explained by the short plasma half-life and 
thereby no substantial gain in the tumour accumulation with the increase of the dose. 
Importantly, a further increase in the dose of DTX-CCL-PMs to 125 mg/kg induced complete 
regression of the tumours leading to 100% tumour-free survival. These antitumour effects 
were not only limited to the early stage tumours but also observed with the late-stage 
(established) tumours, which were completely suppressed with a single dose of DTX-CCL-
PMs (Fig. 3). Complete regression of established tumours is highly challenging and rarely 
achieved in preclinical studies. Huang et al. reported profound regression of MDA-MB-231 
tumours after multiple injections of DTX-loaded self-assembled nanoparticles, yet complete 
tumour regression was not achieved [24]. Similarly, substantial tumour regression was 
observed in the same breast cancer xenografts, although three i.v. injections of NC-6301 
(polymeric micelles of DTX) at a 4-day interval were required [49]. In the present study, the 
remarkable therapeutic effects already obtained with a single dose of DTX-CCL-PMs 
highlight the potent antitumour activity of DTX-CCL-PMs and its potential for clinical 
application.  
Since DTX is an antimitotic drug, it is primarily assumed to display its antitumour activity 
through tumour cell growth inhibition. However, interestingly we found that treatment with 
DTX-CCL-PMs also led to the reduction in tumour stromal components such as pericytes (-
SMA, NG2), fibroblasts (-SMA) and extracellular matrix (collagen-1) at 96 h after a single 
dose administration (Fig. 4). In the tumour microenvironment, fibroblastic cells produce 
excessive extracellular matrix such as collagen, which induces tumour rigidity, less perfusion 
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and increase in interstitial fluid pressure [50]. In addition, pericytes support endothelial cells 
and thereby the maturation of blood vessels during angiogenesis leading to enhanced nutrition 
supply to tumours. Inhibition of these components is highly essential to achieve complete 
regression of tumours. In contrast to DTX-CCL-PMs, treatment with Taxotere showed only a 
mild reduction in pericyte marker (NG2). These data corroborate with the recent findings of 
Murakami and coworkers who showed a reduction in collagen and -SMA in orthotopic 
MDA-MB-231 tumour model after the treatment with a DTX-conjugate nanoparticle 
formulation (PEGylated acetylated carboxymethylcellulose-docetaxel conjugate) named 
Cellax [51]. Our data suggest that the observed antitumour effects of DTX-CCL-PMs are at 
least partially mediated through the depletion of tumour stroma in addition to the direct effect 
on tumour cells. 
In addition to the studies in tumour-bearing mice, preclinical PK and tolerability studies were 
carried out in healthy rats as part of the clinical translation program of DTX-CCL-PMs. In the 
PK studies, the blood levels in healthy rats revealed that DTX-CCL-PMs remained in the 
circulation for extended periods of time (t1/2 = 16.2 h) and total DTX was detected in blood up 
to 7 days after a single dose of DTX-CCL-PMs (7.5 mg/kg) (Fig. 5B). Importantly, this 
demonstrates that DTX remained entrapped in PMs for several days due to the transiently 
stable covalent linkage. With respect to tolerability, DTX-CCL-PMs at 9.7 mg/kg was much 
better tolerated by rats as compared to a lower dose of Taxotere (6.7 mg/kg) (Table S3-S5). 
The superior tolerability of DTX-CCL-PMs is likely attributed to the blood circulation profile 
of the intact nanoparticles and thereby the absence of high DTX blood levels and significantly 
improved volume of distribution at steady state (0.06 L/kg) as compared to Taxotere (4 L/kg) 
[52]. It is of interest that major DTX dose limiting toxicities observed in the clinic such as 
diarrhea, pan-leukopenia and effects on immunologically related tissues occurred at a lesser 
severity and/or incidence in the DTX-CCL-PMs treated rats as compared to animals that 
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received Taxotere. Together with other assays as required by regulatory authorities, these 
preliminary results of toxicology evaluation advocate the clinical translation of DTX-CCL-
PMs. 
5. Conclusions 
In conclusion, this study demonstrates the development of a novel docetaxel-containing 
nanomedicine of which a single dose can regress both early and established human xenograft 
tumours completely, providing 100% tumour-free survival to these animals. Importantly, 
DTX-CCL-PMs were well tolerated by animals at the examined doses, showing superior 
tolerability to the marketed Taxotere formulation. Altogether, the improved therapeutic index 
of DTX-CCL-PMs and straightforward manufacturability strongly support its clinical 
development. 
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Table 1. Pharmacokinetic evaluation for total docetaxel levels in whole blood after a single i.v. 
administration of DTX-CCL-PMs to female rats at different doses (n=6).  
 
DTX-CCL-PMs 
1.5 mg/kg 
DTX-CCL-PMs 
7.5 mg/kg 
DTX-CCL-PMs 
24 mg/kg 
C0 (µg/mL) 12.6 114.2 364.6 
t1/2 (h) 15.1 16.2 16.4 
AUC0-∞ (µg*h/mL) 229.8 1948.1 5808.9 
AUC0-∞/Dose 
(g*h/mL) 
158.5 266.9 240.0 
Vz (mL/kg) 137.2 60.0 67.9 
Vss (mL/kg) 129.5 56.1 62.3 
The values are calculated by PK analysis using a non-compartmental model.  
C0 = concentration at t=0, extrapolated, t1/2 = elimination half-life, AUC0-∞ = extrapolated area under the curve 
from zero to infinity, Vz = volume of distribution and Vss = volume of distribution at steady state. 
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Figure Captions 
Fig. 1. Synthesis and characterization of DTX-CCL-PMs. (A) Synthesis scheme of DTX-derivative (DTXL), 
linker =2-(2-(methacryloyloxy)ethylthio)acetic acid; (B) Particle size distribution of DTX-CCL-PMs as determined 
by dynamic light scattering; (C) Transmission electron microscopical image of DTX-CCL-PMs and (D) 
Representative in vitro release of DTX and 7-epi-DTX (a major degradation product of DTX) from DTX-CCL-PMs 
in PBS (pH 7.4), rat blood and human blood at 37
o
C. The first measurement time point was at 1 hour after the 
onset of incubation at 37
o
C. 
 
Fig. 2. Antitumour effect of DTX-CCL-PMs at a single dose of 30 and 60 mg DTX/kg. (A) Tumour growth 
curve and (B) % survival of mice bearing MDA-MB-231 xenografts after a single i.v. injection of Taxotere or DTX-
CCL-PMs at equivalent doses (30 and 60 mg DTX/kg). The vehicle group received ammonium acetate buffer (20 
mM, pH 5) containing 130 mM NaCl. The duration of the study was 79 days. Data are expressed as the mean ± 
SEM (n=8).  
 
Fig. 3. Antitumour effect of DTX-CCL-PMs (125 mg DTX/kg) in early and established MDA-MB-231 
xenografts tumours. (A) Tumour growth curve and (B) % survival of tumour-bearing mice after a single i.v. 
injection of Taxotere (30 mg DTX/kg), DTX-CCL-PMs (125 mg DTX/kg) or vehicle (when tumours attain ~150 
mm
3
 size, depicted as day 1). The vehicle group received ammonium acetate buffer (20 mM, pH 5) containing 
130 mM NaCl. (C) Tumour growth curve and (D) % survival of tumour-bearing mice after a single i.v. injection of 
Taxotere (30 mg DTX/kg) or DTX-CCL-PMs (125 mg DTX/kg) (when tumours attain ~550 mm
3
 size, depicted as 
day 10). The duration of the study was 62 days. Data are expressed as the mean ± SEM (n=10).  
 
Fig. 4. Intratumoural effect of DTX-CCL-PM on tumour stroma. Western blot analyses in tumour samples 
collected 4 days after a single i.v. injection of Taxotere (30 mg DTX/kg), DTX-CCL-PMs (125 mg DTX/kg) or 
vehicle. The vehicle group received ammonium acetate buffer (20 mM, pH 5) containing 130 mM NaCl. (A) 
Treatment scheme; (B) Protein bands of Western blot and (C) Semi-quantitative analyses of the bands. Data are 
expressed as the mean ± SEM (n=3). *P<0.05 versus vehicle, 
#
P<0.05 versus Taxotere. 
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Fig. 5. Pharmacokinetics and tumour accumulation of DTX-CCL-PMs. (A) Intratumoural levels of released 
DTX and total DTX (released + entrapped) after a single i.v. injection of Taxotere (30 mg DTX/kg) or DTX-CCL-
PMs (30 mg DTX/kg) in mice bearing MDA-MB-231 xenografts. Data are expressed as the mean ± SEM (n=3), 
*P<0.05, **P< 0.01, ***P< 0.001. (B) Total DTX (released + entrapped) levels in blood after a single i.v. injection 
of DTX-CCL-PMs (7.5 mg DTX/kg) in healthy female rats. Data are expressed as the mean ± SEM (n=6) and (C) 
Correlation between the injected dose and AUC0-∞ for DTX-CCL-PMs in healthy rats after a single i.v. injection of 
DTX-CCL-PMs at 1.5, 7.5 and 24 mg DTX/kg, respectively (R
2
=0.997).  
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